The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial.
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Paige M. Bracci
No Relationships to Disclose
 
Bridget Keenan
Research Funding - Partner Therapeutics (Inst)
 
Spencer Behr
Consulting or Advisory Role - Advanced Accelerator Applications; GenVivo; More Health; Progenics
Research Funding - Cancer Targeted Technology
 
Faaiz Ibrahim
No Relationships to Disclose
 
Marin Pollak
No Relationships to Disclose
 
John Gordan
Consulting or Advisory Role - Genentech/Roche
Research Funding - ShangPharma Innovation (Inst)
Patents, Royalties, Other Intellectual Property - A small molecule patent has been submitted for a tool compound developed in my academic research, and is currently in provisional form. It has no current health applications but may eventually be developed into a clinically relevant compound. (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Medscape; PER; PlatformQ Health; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Gritstone Bio; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
Katherine Van Loon
Speakers' Bureau - Amgen; Physicans' Education Resource
Research Funding - Celgene (Inst)
 
Chloe Evelyn Atreya
Stock and Other Ownership Interests - Pionyr
Consulting or Advisory Role - Array BioPharma; Inivata; Pfizer; Pionyr
Research Funding - Bristol-Myers Squibb (Inst); Gossamer Bio (Inst); Guardant Health (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Roche
 
Pelin Cinar
Consulting or Advisory Role - Astellas Pharma
 
Alan P. Venook
Consulting or Advisory Role - Amgen; BridgeBio Pharma; Exelixis; GlaxoSmithKline; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Lawrence Fong
Stock and Other Ownership Interests - Alector; Alector; Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio; TeneoBio
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Janssen Oncology; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)